Search results for "hepatotoxicity"

showing 10 items of 24 documents

Metabolism and Bioactivation of Corynoline With Characterization of the Glutathione/Cysteine Conjugate and Evaluation of Its Hepatotoxicity in Mice

2018

Corynoline (CRL), an isoquinoline alkaloid, is the major constituent derived from Corydalis bungeana Herba, which is a well-known Chinese herbal medicine widely used in many prescriptions. The purpose of this study was to comprehensively investigate the metabolism and bioactivation of CRL, and identify the CYP450 isoforms involved in reactive ortho-benzoquinone metabolites formation and evaluate its hepatotoxicity in mice. Here, high resolution and triple quadrupole mass spectrometry were used for studying the metabolism of CRL. Three metabolites (M1-M3) and four glutathione conjugates (M4-M7) of CRL ortho-benzoquinone reactive metabolite were found in vitro using rat and human liver micros…

0301 basic medicinehepatotoxicityCorynolinePharmacology03 medical and health scienceschemistry.chemical_compoundPharmacology (medical)corynolineCYP450 enzymesOriginal Researchmass spectrometryPharmacologybioactivationCYP3A4Alkaloidlcsh:RM1-950fungifood and beveragesMetabolismGlutathionelcsh:Therapeutics. Pharmacology030104 developmental biologychemistryToxicityMicrosomemetabolismCysteineFrontiers in Pharmacology
researchProduct

Unexplained chronic liver disease in Ethiopia: a cross-sectional study

2018

Background Hepatitis B virus (HBV) infection is assumed to be the major cause of chronic liver disease (CLD) in sub-Saharan Africa. The contribution of other aetiological causes of CLD is less well documented and hence opportunities to modulate other potential risk factors are being lost. The aims of this study were to explore the aetiological spectrum of CLD in eastern Ethiopia and to identify plausible underlying risk factors for its development. Methods A cross-sectional study was undertaken between April 2015 and April 2016 in two public hospitals in Harar, eastern Ethiopia. The study population comprised of consenting adults with clinical and radiological evidence of chronic liver dise…

MaleCross-sectional studyEpidemiologyBiopsyChronic liver disease0302 clinical medicineRisk FactorsKhatEpidemiologyPrevalenceSIMPLE NONINVASIVE INDEX030212 general & internal medicineViral hepatitisPOPULATIONbiologymedicine.diagnostic_testSub-Saharan AfricaLiver DiseasesGastroenterologyCHRONIC HEPATITISGeneral MedicineAlcoholismLiverLiver biopsyPopulation studyFemale030211 gastroenterology & hepatologyC HEPATITISViral hepatitisLife Sciences & BiomedicineResearch ArticleAdultmedicine.medical_specialtySubstance-Related DisordersAcute Lung InjuryKHAT LEAVESAUTOIMMUNEVERBAL AUTOPSY METHODCathaVIRUS-INFECTIONCatha edulis03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Science & TechnologyGastroenterology & HepatologySIGNIFICANT FIBROSISbusiness.industryHepatotoxicity1103 Clinical SciencesHepatologybiology.organism_classificationmedicine.diseaseCross-Sectional StudiesChronic Diseaselcsh:Diseases of the digestive system. GastroenterologyEthiopiabusiness
researchProduct

Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication

2010

Abstract Background and aims Drug-induced liver injury (DILI) is the most common cause of death from acute liver failure, and accounts for approximately 13% of cases of acute liver failure in the United States. The clinical presentation of DILI covers a wide spectrum, from asymptomatic liver test abnormalities to symptomatic acute liver disease, prolonged jaundice and disability, or overt acute or subacute liver failure. The aim of our study was to evaluate the number of DILI cases admitted to our Unit and to identify the drugs responsible. Thus, we reviewed all clinical records of patients with DILI admitted to our Unit from 1996 to 2006. Patients and methods A database was constructed, re…

AdultMalemedicine.medical_specialtyEncephalopathySex FactorsAnti-Infective AgentsInternal medicineAscitesmedicineHumansAgedRetrospective StudiesNimesulideLiver injuryPsychotropic DrugsSulfonamidesHepatologymedicine.diagnostic_testbusiness.industryAnti-Inflammatory Agents Non-SteroidalHepatotoxicityAge FactorsGastroenterologyMiddle AgedJaundicemedicine.diseaseSurgeryDiscontinuationHepatotoxicity; Liver function tests; NimesulideLiver function testFemaleChemical and Drug Induced Liver Injurymedicine.symptombusinessLiver function testsLiver FailureAdverse drug reactionNimesulidemedicine.drugDigestive and Liver Disease
researchProduct

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

2019

AbstractObjectivesTo evaluate the incidence and risk factors for liver enzyme elevations (LEE) in patients initiating first-line ART in the ICONA prospective observational cohort, between June 2009 and December 2017.Patients and methodsIn total, 6575 ART-naive patients were selected, initiating two NRTIs with the third drug being a boosted PI (n=2436; 37.0%), an NNRTI (n=2384; 36.3%) or an integrase strand transfer inhibitor (INSTI) (n=1755; 26.7%). HBV surface antigen and HCV RNA were detected in 3.9% and 5.8% of the study population. Inverse probability weighted Cox regression analysis was used to calculate the HRs, according to first-line regimen, for LEE, defined as ALT or AST increases…

0301 basic medicineMaleIntegrase inhibitorHepatitis B Surface AntigenHIV Infections0302 clinical medicineRisk Factorshivh epatitis c rna surface antigens follow-up homosexuality integrase inhibitors hepatitis b virus hepatitis b virus measurement hiv infections hepatotoxicity hepatitis c virus coinfection nucleoside reverse transcriptase inhibitors non-nucleoside reverse transcriptase inhibitors cox proportional hazards models baseline value liver enzyme raltegravirPharmacology (medical)HIV Infection030212 general & internal medicineProspective StudiesProspective cohort studyCoinfectionIncidence (epidemiology)Liver DiseaseIncidenceLiver Diseasesvirus diseasesHepatitis CMiddle AgedHepatitis CReverse Transcriptase InhibitorInfectious DiseasesCohortCoinfectionPopulation studyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.drugHumanMicrobiology (medical)Adultmedicine.medical_specialtyAnti-HIV AgentsRegression AnalysiNO03 medical and health sciencesInternal medicinemedicineHumansHIV Integrase InhibitorsHIV Protease InhibitorPharmacologyHepatitis B Surface Antigensbusiness.industryAnti-HIV AgentHIV ARTHIV Protease Inhibitorsmedicine.diseaseRaltegravir030112 virologyHIV Integrase InhibitorProspective StudieHIV-1businessAdult Anti-HIV Agents Coinfection Female Hepatitis B Surface Antigens Hepatitis C HIV Infections HIV Integrase Inhibitors HIV Protease Inhibitors HIV-1 Humans Incidence Liver Diseases Male Middle Aged Prospective Studies Regression Analysis Reverse Transcriptase Inhibitors Risk Factors
researchProduct

Cytometric analysis for drug-induced steatosis in HepG2 cells

2009

Drugs are capable of inducing hepatic lipid accumulation. When fat accumulates, lipids are primarily stored as triglycerides which results in steatosis and provides substrates for lipid peroxidation. An in vitro multiparametric flow cytometry assay was performed in HepG2 cells by using fluorescent probes to analyze cell viability (propidium iodide, PI), lipid accumulation (BODIPY493/503), mitochondrial membrane potential (tetramethyl rhodamine methyl ester, TMRM) and reactive oxygen species generation (ROS) (2',7'-dihydrochlorofluorescein diacetate, DHCF-DA) as functional markers. All the measurements were restricted to live cells by gating the cells that excluded PI or those that exhibited…

Drug-induced steatosisBiologyToxicologyFluorescenceCell LineFlow cytometryLipid peroxidationchemistry.chemical_compoundIn vivomedicineMultiparametric assayHumansMTT assayPropidium iodideViability assayFlow cytometryHepG2 cellsmedicine.diagnostic_testIn vitro hepatotoxicityGeneral MedicineFlow Cytometrymedicine.diseaseMolecular biologyFatty LiverchemistryCell cultureSteatosisReactive Oxygen Species
researchProduct

Factors that influence the quality of metabolomics data in in vitro cell toxicity studies: a systematic survey

2021

Abstract REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) is a global strategy and regulation policy of the EU that aims to improve the protection of human health and the environment through the better and earlier identification of the intrinsic properties of chemical substances. It entered into force on 1st June 2007 (EC 1907/2006). REACH and EU policies plead for the use of robust high-throughput "omic" techniques for the in vitro investigation of the toxicity of chemicals that can provide an estimation of their hazards as well as information regarding the underlying mechanisms of toxicity. In agreement with the 3R’s principles, cultured cells are nowadays wide…

Quality ControlHEPATOTOXICITYSciencemedia_common.quotation_subjectDiseasesComputational biologyMETABOLISMBiologyHEPATOCYTESCitric AcidArticleXenobioticsProductes químicschemistry.chemical_compoundMetabolomicsMedical researchCell Line TumorMetabolomeHumansMetabolomicsSPECTROMETRY DATAQuality (business)HEPARG CELLSAcetaminophenmedia_commonBATCH EFFECT CORRECTIONMultidisciplinaryFATTY-ACIDDrug discoveryValproic AcidQRReproducibility of ResultsHep G2 CellsIn vitroBioactive compoundGLUTAMINEMetabolic pathwayLiverchemistryToxicityMetabolomeMedicineCURRENT STATEChemical and Drug Induced Liver InjuryXenobioticMetabolic Networks and PathwaysBiomarkersVALPROATEScientific Reports
researchProduct

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review.

2022

Aims: N-Acetylcysteine (NAC) is used as an antidote in acetaminophen (APAP) overdose to prevent and mitigate drug-induced liver injury (DILI). Our objective was to systematically review evidence of the use of NAC as a therapeutic option for APAP overdose and APAP-related DILI in order to define the optimal treatment schedule and timing to start treatment.Methods: Bibliographic databases (PubMed, Web of Science, Embase, and MEDLINE) were searched for retrospective and prospective cohort studies, case series, and clinical trials. The prespecified primary outcomes were DILI-related mortality, hepatotoxicity, and adverse events (AEs).Results: In total, 34 studies of NAC usage in APAP-related DI…

PharmacologysafetyhepatotoxicitySettore MED/09 - Medicina InternaPharmacology (medical)N-acetyl-cysteinedrug-induced liver injuryacetaminophen
researchProduct

Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells

2010

BACKGROUND AND PURPOSE Efavirenz (EFV) is widely used in the treatment of HIV-1 infection. Though highly efficient, there is growing concern about EFV-related side effects, the molecular basis of which remains elusive. EXPERIMENTAL APPROACH In vitro studies were performed to address the effect of clinically relevant concentrations of EFV (10, 25 and 50 mu M) on human hepatic cells. KEY RESULTS Cellular proliferation and viability were reduced in a concentration-dependent manner. Analyses of the cell cycle and several cell death parameters (chromatin condensation, phosphatidylserine exteriorization, mitochondrial proapoptotic protein translocation and caspase activation) revealed that EFV tr…

CyclopropanesMalehepatotoxicityCarcinoma HepatocellularTime FactorsAnti-HIV AgentsCell SurvivalApoptosisMitochondria LiverPhosphatidylserinesAntioxidantsSuperoxidesHumansChromansantiretroviral drugsCell Proliferationreactive oxygen speciesDose-Response Relationship DrugCell CycleLiver NeoplasmsChromatin Assembly and DisassemblyResearch PapersGlutathioneBenzoxazinesmitochondriaOxidative Stressside effectscell deathLiverAlkynesFemaleEfavirenzApoptosis Regulatory ProteinsHeLa Cells
researchProduct

Metabolomics as a tool for the study of drug-induced hepatotoxicity

2015

Drug-induced liver injury (DILI) is a major health and economic problem and the leading cause of hepatic dysfunction, drug failure during clinical testing and post-market withdrawal of approved drugs. Pre-clinical testing should be able to detect potential hepatotoxins early in the drug development process in order to minimize health risks and financial losses. Several liver-derived in vitro models have been developed to be used in pharmacology and toxicology research to understand the mechanism of DILI and to evaluate potential hepatotoxicity of new chemical entities. Although they fail to reproduce the complexity of a whole organ, their low cost, high reproducibility, and the possibility …

UNESCO::CIENCIAS MÉDICAS ::Toxicología:QUÍMICA::Química analítica::Espectroscopía de masas [UNESCO]UNESCO::QUÍMICA::Química analítica::Espectroscopía de masashepatotoxicity:QUÍMICA::Química analítica::Análisis cromatográfico [UNESCO]UNESCO::QUÍMICA::BioquímicaUNESCO::QUÍMICA::Química analítica::Análisis cromatográfico:QUÍMICA::Bioquímica [UNESCO]metabolomics:CIENCIAS MÉDICAS ::Toxicología [UNESCO]lc-ms
researchProduct

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

2021

Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and age…

0301 basic medicinehepatotoxicityNevirapineEfavirenzQH301-705.5030106 microbiologyEtravirinecARTReviewBioinformaticsliver03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineDoravirinemedicineAnimalsHumans030212 general & internal medicineBiology (General)antiretroviral drugsbusiness.industryFatty livervirus diseasesHIVGeneral Medicinemedicine.diseasechemistryRilpivirineChronic DiseaseReverse Transcriptase InhibitorsDrug Therapy CombinationDILIChemical and Drug Induced Liver InjuryViral hepatitisbusinessmedicine.drugCells
researchProduct